

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai-400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413

14th November, 2014.

To,
✓ Mrs. S. Subramanian. DCS-CRD
✓ The Secretary
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
"Exchange Plaza", C-1, Block - G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.

Ref: Compliance of Clause 41 of the Listing Agreement**Script Code: 532637****Symbol: MANGALAM**

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter and half year ended 30th September, 2014.

In terms of Clause 41 of the Listing Agreement(s), we are forwarding herewith Unaudited Financial Results for the quarter and half year ended 30th September, 2014 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 14th November, 2014 at Mumbai along with Limited Review Report of the said period.

Further please note that the Company has made necessary arrangement to publish the same in the newspaper as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.


(GOVARDHAN M. DHOOT)
DIRECTOR



A Un-Audited Financial Results (Provisional) for the Quarter and Half Year ended 30th September 2014							
(Rs. in Lacs)							
Sr. No.	Particulars	Unaudited			Unaudited		Audited
		Quarter ended		Corresponding 3 months ended in the previous period	Half year ended		Year Ended
		3 months ended	3 months ended		Year to date figures for Current period ended	Year to date figures for the previous period ended	
		30.09.14	30.06.14	30.09.13	30.09.14	30.09.13	31.03.14
1	Sales/Income from operation (Net of Excise duty)	4084.93	3855.81	2812.68	7940.74	4648.15	12231.97
2	Other Operating Income	284.97	7.74	8.61	272.71	17.54	35.78
3	Total Net Income from Operation	4369.90	3863.55	2821.29	8213.45	4865.69	12267.75
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	(214.57)	(152.16)	(116.08)	(366.73)	(501.07)	(544.63)
	(b) Consumption of raw materials	2664.08	2785.71	1788.18	5729.79	3574.73	8374.88
	(c) Employee Benefits	275.09	253.18	266.80	528.27	511.07	1024.55
	(d) Depreciation	93.83	106.90	98.79	200.53	197.28	401.05
	(e) Other expenditure	745.16	641.06	830.38	1386.22	1092.14	2436.55
	(f) Total	3693.39	3614.89	2668.07	7478.08	4874.15	11692.40
5	Profit/(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	486.51	248.66	153.22	735.37	(208.46)	675.35
6	Other income	2.69	2.19	0.00	4.88	1.98	8.23
	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	489.20	251.05	153.22	740.25	(206.48)	583.58
8	Finance Cost	273.84	271.35	250.13	544.99	476.99	874.21
	Profit/(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	215.56	(20.30)	(96.91)	195.26	(683.47)	(390.63)
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit/(+)/Loss(-) before Tax (9-10)	215.56	(20.30)	(96.91)	195.26	(683.47)	(390.63)
12	Tax Expenses (incl Deferred Tax)	15.00	0.00	0.00	15.00	0.00	(86.71)
13	Net Profit/(+)/Loss(-) after Tax (11-12)	200.56	(20.30)	(96.91)	180.26	(683.47)	(303.92)
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit/(+)/Loss(-) for the period(13-14)	200.56	(20.30)	(96.91)	180.26	(683.47)	(303.92)
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1004.48
13	Earning per share (EPS)						
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.52	(0.15)	(0.74)	1.37	(5.19)	(2.31)
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.52	(0.15)	(0.74)	1.37	(5.19)	(2.31)
14	Non Promoters Shareholding						
	- Number of shares	7628115	7628115	7548453	7628115	7548453	7628115
	- Percentage of shareholding	57.88	57.88	57.28	57.88	57.28	57.88
15	Promoters and Promoter group Shareholding						
	a) Pledged/ Encumbered						
	Number of Shares	5481228	5491228	5448708	5481228	5448708	5491228
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	98.94	98.94	96.78	98.94	96.78	98.94
	Percentage of Shares (as a % of the total share capital of the company)	41.67	41.67	41.35	41.67	41.35	41.67
	b) Non-encumbered						
	Number of Shares	58905	58905	181087	58905	181087	58905
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	1.06	1.06	3.22	1.06	3.22	1.06
	Percentage of Shares (as a % of the total share capital of the company)	0.45	0.45	1.37	0.45	1.37	0.45
16	Investors Complaints:	3 Months ended 30.09.14					
	Pending at the Beginning of the Quarter	Nil					
	Received during the Quarter	Nil					
	Disposed of during the Quarter	Nil					
	Remaining unresolved at the end of the Quarter	Nil					


Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 14th November 2014
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- Previous year figure are regrouped wherever necessary.

For MILWANI ASSOCIATES
Chartered Accountants

Place: Mumbai
Date: 14.11.2014

(CA Rakesh K. Milwani) Proprietor
Membership No. 306000
F.R.N. 306000



On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

Chairman
(Shri Govardhan M. Dhoot)


MANGALAM DRUGS & ORGANICS LTD.			
Statement Of Assets & Liabilities (To-Auditors) As at 30th Sept 2014, Required Under Clause 41 OF Listing Agreement			
S.No.	Particulars	Half Year ended (Un-audited)	(Rs. In Lacs)
		30.09.2014	31.03.2014
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,317.82	1,317.82
	(b) Reserves and surplus	1,184.73	1,004.47
	Sub Total -Shareholders Funds	2,502.55	2,322.29
2	Non-current liabilities		
	(a) Long-term borrowings	4,039.20	4,020.21
	(b) Deferred Tax Liabilities (Net)	58.56	58.56
	Sub Total -Non-Current Liabilities	4,097.76	4,078.77
3	Current liabilities		
	(a) Short-term borrowings	2,985.40	3,136.67
	(b) Trade payables	1,456.42	2,086.73
	(c) Other current liabilities	925.82	919.97
	Sub Total -Current Liabilities	5,367.64	6,143.37
	TOTAL	11,967.95	12,544.43
B	ASSETS		
1	Non-current assets		
	(a) Fixed Assets	5244.43	5338.43
	(b) Long-term loans and advances	258.78	239.77
	Sub Total -Non-Current Assets	5,503.21	5,578.20
2	Current assets		
	(a) Current Investments	24.01	17.92
	(b) Inventories	3,545.74	3,647.76
	(c) Trade receivables	2,282.02	2,968.73
	(d) Cash and cash equivalents	24.14	10.23
	(e) Short-term loans and advances	588.83	321.59
	Sub Total -Current Assets	6,464.74	6,966.23
	TOTAL	11,967.95	12,544.43

Notes: 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: 14.11.2014

For **MILWANI ASSOCIATES**
Chartered Accountants

(CA Rakesh K. Milwani) Proprietor
Membership No.: 30090
F.R.N.: 1064059



On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

Chairman
(Shri Govardhan M. Dhoot)

FROM : MANGALAM DRUGS AND ORGANICS LT FAX NO. : 0091 22 22087074 Nov. 14 2014 01:37AM P4

CA Rakesh K. Milwani
B.Com., LL.B., FCA**MILWANI ASSOCIATES**
CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.

Tel : 22036132/9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.**LIMITED REVIEW REPORT**

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at Rupam Building, 3rd Floor, 239 P.D'Mello Road, Near GPO, Mumbai - 400001; for the quarter and half year ended 30th Sept'2014 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any

Place : Mumbai

Date : 14th November 2014.

PROPRIETOR: MILWANI ASSOCIATES

Firm Registration No.: 106405W

(CA Rakesh K. Milwani) Proprietor

Membership No. 36099

